Introduction
Suicide gene therapy has been studied intensively and extensively both in animal models and in patients. 1, 2 Cytosine deaminase (CD) gene exists in bacteria and fungi, but not in mammalian cells. 5-Fluorocytosine (5FC), being widely used for the treatment of fungi and bacteria infections, could be metabolized by CD to 5-fluorouracil (5-FU), a highly toxic agent for the treatment of malignant tumors. The growth of tumor cells modified to express CD could be significantly inhibited by 5FC both in vitro and in vivo. Many animal experiments and clinical trials demonstrated that tumor relapse or metastasis often occurred after suicide gene therapy, which might be due to the limited induction of antitumor immunity. 3 To address this limitation, in our previous investigation, we have demonstrated that cotransfection of interleukin-2 (IL-2), granulocyte-macrophage colonystimulating factor (GM-CSF) or lymphotactin genes could greatly increase the antitumor effects of CD gene therapy and induced potent antitumor immunity, but no direct restricted, B16 melanoma-specific CD8 + T cells. B16 specific H-2K b /TRP2 180-188 tetramer was used to stain the tumorspecific CD8
+ T cells and the results showed that CD8 + tetramer + T cells were about 3-5% of the splenic CD8 + T cells derived from tumor-bearing mice after combined therapy. The CTL cytotoxicity was markedly induced in mice after combined therapy, suggesting efficient induction of tumor-specific CD8 + T cells after combined gene therapy with AdCD/5FC/AdIL18. IL-18 gene transfer could significantly augment the cytotoxicity of NK cells and macrophages, and increase the production of interleukin-2 and interferon-␥, as compared with treatments with AdCD/5FC, AdlacZ/5FC or PBS. These data suggested that in vivo IL-18 gene transfer could augment the antitumor effects of CD suicide gene therapy through efficient induction of antitumor immunity. Gene Therapy (2000) 7, 1672-1679.
evidence was presented to show the induction of tumor specific CTL after the combined suicide gene and cytokine gene therapy. [4] [5] [6] Although it is widely accepted that induction of CD8 + T cells is of crucial importance in gene therapy and immunotherapy, and quantitative analysis of tumorspecific T cell populations will provide important information on the mechanisms of antitumor immune responses, there was no direct approach to quantifying the antigen-specific T cells with their ligands in recent years because monomeric soluble peptide-MHC complexes have an inherently fast dissociation rate from the T cell antigen receptor. 7 Recently, tetrameric peptide/MHC complexes (tetramer) have been engineered to identify antigen-specific CTLs after acute or chronic viral infections both in animals and in patients. [8] [9] [10] [11] [12] [13] [14] Up to now, there are few reports on the identification of tumor antigenspecific CTL in tumor-bearing hosts after gene therapy or immunotherapy.
Therefore, in the present study, we first examined the antitumor effects of combined interleukin-18 (IL-18) gene and CD gene theray. Th1 cytokine IL-18 gene transfer was expected to induce more potent antitumor immunity in CD suicide gene therapy, because IL-18 was reported to increase CTL induction and drive type 1 cytokine production from NK cells and T cells.
15, 16 Then, we prepared tetramer H-2K   b   /TRP-2 180-188 , which could stain B16 melanoma specific CTL, and analyzed the induction of tumorspecific antitumor immunity in tumor-bearing mice after  combined CD gene and IL-18 gene therapy. TRP-2 is a  tumor specific antigen identified in murine B16  melanoma with a CTL epitope TRP-2 180-188 presented by  H-2K b . 17 The results demonstrated that IL-18 gene transfection could significantly enhance the therapeutic effects of CD suicide gene therapy through efficient induction of antitumor immunity.
Results
Enhanced therapeutic effects of combined IL-18 and suicide gene therapy To increase the antitumor effects and induce more potent antitumor immunity of CD suicide gene therapy, adenovirus-mediated IL-18 gene transfer was combined with AdCD/5FC gene therapy in the pre-established murine model with B16 melanoma. The data in Figure 1a show that treatment of the tumor-bearing mice with intratumoral IL-18 gene transfer suppressed the growth of the Gene Therapy established tumor significantly as compared with treatment with AdlacZ/5FC or PBS (P Ͻ 0.01). AdCD/5FC gene therapy alone showed similar antitumor effects with AdIL18 gene therapy. Combination treatment of the tumor-bearing mice with AdIL18 and AdCD/5FC inhibited the growth of the subcutaneous B16 tumors more significantly as compared with AdIL18 alone or AdCD/5FC alone (P Ͻ 0.01). Eighty percent of the tumorbearing mice were tumor-free 3 months after the combined therapy. The surviving tumor-free mice were rechallenged with wild B16 cells, and four of four mice treated with AdCD/5FC/AdIL18 were tumor free after another 3 months, but all four surviving mice treated with AdCD/5FC/AdIL18 challenged with syngeneic EL4 tumor cells died within 2 months of tumor inoculation. These data suggested that potent antitumor immunity was induced in mice after combined suicide gene and IL-18 gene therapy (Table 1) .
In vivo depletion analysis with anti-CD4, anti-CD8 or anti-NK 1.1 monoclonal antibody was performed to elucidate the roles of different lymphocyte subsets in mediating the antitumor immune response of the AdIL18/AdCD/5FC combined gene therapy. The results illustrated that the tumor-bearing mice undergoing combined therapy and injected with anti-CD8 antibody showed larger tumors when compared with AdIL18/AdCD/5FC-treated mice injected with control IgG or PBS (P Ͻ 0.01). Suprisingly, depletion of CD4 + T cells of the tumor-bearing mice with anti-CD4 antibody also significantly impaired the antitumor effects of AdIL18/AdCD/5FC. These data indicated that that both CD8 + T cells and CD4 + T cells played key roles in the enhanced antitumor response of the combined therapy. Depletion of NK cells with anti-NK1.1 antibody also partially decreased the antitumor effects of AdIL18/AdCD/5FC combined gene therapy (Figure 1b) , suggesting that NK cells also contribute to the augmented antitumor effects of AdIL18/AdCD/5FC.
Induction of B16 melanoma-specific CD8
+ T cells after AdIL18/AdCD/5FC therapy Tetrameric MHC-peptide complexes were successfully used for the staining of MHC-I-or MHC-II-restricted T Tumor-free mice after combined treatment with AdCD/5FC/ AdIL18 were rechallenged with wild-type 2 × 10 4 B16 or EL4 tumor cells and data demonstrating tumor-free mice after another 3 months. c Naive mice received neither tumor inoculation nor suicide gene therapy. These mice were challenged with B16 cells as control. cell subsets. 18, 19 In this study, we constructed plasmid harboring truncated extra-membrane H-2K b gene fused with cDNA encoding specific biotinylation site at the COOH end. After biotinylation and tetramerization, the specificity of the staining of the H-2K b /TRP2 180-188 tetramer was tested utilizing CTL clone which was reactive with TRP2 180-188 or H-2K b -restricted CD8 + T cell hybridoma RF33.70 which was reactive with OVA 257-264 . 17 As shown in Figure TRP2 is a specific H-2K b restricted tumor antigen derived from B16 melanoma. 17 The 180-188 amino acid of TRP-2 was identified as the epitope recognized by CTL isolated from B16 immunized mice (James Yang, NCI, NIH, Bethesda, MD, USA). As described above, we prepared specific H-2K b /TRP2 180-188 tetramer to stain the tumor-specific CD8 + T cells in tumor-bearing mice treated with AdIL18 and/or AdCD/5FC gene therapy. The results in Figure 3 a-e showed that in mice after com- Figure 4 demonstrated that no significant specific lytic activity was induced by these lymphocytes derived from AdCD/5FC-, AdlacZ/5FC-or PBS-treated mice. Obviously higher CTL activity was found with the lymphocytes from mice treated with AdIL18 administration (P Ͻ 0.05). The CTL cytotoxicity was even higher in mice after combined therapy with AdIL18/AdCD/5FC when compared with that from mice treated with AdIL18 (P Ͻ 0.05). These data suggested tumor-specific CD8 + T cells were induced efficiently after combined AdIL18/AdCD/5FC therapy.
Increased cytotoxicity of NK and macrophages after combined AdIL18/AdCD/5FC therapy The lymphocytes derived from tumor-bearing mice after various gene therapies were used as NK effector cells to test their cytotoxicity against YAC-1 cell. The results in Figure 5a showed that IL-18 gene transfection, in the presence and absence of AdCD/5FC therapy, could augment NK activity significantly as compared with treatments with AdCD/5FC, AdlacZ/5FC or PBS (P Ͻ 0.01). As demonstrated in Figure 5b , the cytotoxicities of splenic macrophages derived from mice treated with AdIL18, or AdIL18/AdCD/5FC were higher than those derived from mice treated with AdCD/5FC, AdlacZ/5FC or PBS (P Ͻ 0.01). There was no difference in NK and macrophage cytotoxicities between mice receiving AdIL18 and AdIL18/AdCD/5FC. These data demonstrated that both NK cells and macrophages were activated significantly throught the transfection of IL-18 gene.
Increased cytokine production after combined AdIL18/AdCD/5FC therapy We also determined the production of IL-2 and IFN-␥ by splenocytes derived from tumor-bearing mice after immunotherapy. The data in Figure 6 show that splenocytes from mice treated with AdIL18 produced significantly higher levels of IL-2 and IFN-␥ than those treated with AdCD/5FC, AdLacZ/5FC or PBS (P Ͻ 0.01). The splenocytes from tumor-bearing mice after combined Gene Therapy
Figure 6 Production IL-2 (a) and IFN-␥ (b) by lymphocytes derived from tumor-bearing mice and stimulated with irradiated B16 cells in vitro.
Cytokine contents were determined by ELISA kits.
treatment with AdIL18/AdCD/5FC produced highest levels of IL-2 and IFN-␥ as compared with those from mice after other treatments. Elevated cytotoxicity of effector cells and increased production of Th1 cytokine indicated that antitumor immunity was efficiently induced by IL-18 gene transfection.
Discussion
Various strategies have been employed to improve the limited induction of antitumor immunity by suicide gene therapy. Glioma cells transduced with CD/HSVtk fusion gene could exhibit enhanced metabolic suicide and radiosensitivity. Double CD and HSVtk suicide gene, but not single gene transfer allowed reliable elimination of tumor cells in vivo through induction of antitumor T cells more efficiently. 20, 21 Cytokine genes were introduced in vivo to increase the antitumor immunity of tumor-bearing host treated with suicide gene therapy. Chen et al 22, 23 have investigated the effectiveness of combination therapy using a HSVtk suicide gene and IL-2 gene for the treatment of metastatic colon carcinoma in the mouse liver. When poorly immunogenic tumor cells were genetically transduced to express the cytokine IL-6 and CD simultaneously, the tumor cells (205-IL6-CD) became highly immunogenic and could be rejected by normal mice without 5FC treatment. 2 Combined transduction of IL-4 gene with HSVtk/GCV therapy showed increased antitumor efficacy in malignant gliomas. 24 We also demonstrated that more potent antitumor effects could be achieved in established tumors by cotransfer of CD suicide gene and GM-CSF, IL-2 or lymphotactin gene. [4] [5] [6] These data demonstrated that the combination of cytokine gene and suicide gene therapy could be more efficient in the induction of antitumor immunity of the host.
Induction of antitumor immunity plays definite roles in gene therapy and immunotherapy of cancer, and inefficient induction of antitumor immunity often leads to tumor relapse or metastasis, which limits the application of gene therapy. CTL represents the most important effector cells for the elimination of residual and metastatic tumor cells. No optimal method was available for the direct analysis of tumor-specific CTL after gene therapy until the utilization of peptide/MHC tetramer. Peptide/MHC tetramer represents a powerful and general tool for rapid, direct analysis of antigen-specific T cells and this technique appears to be exquisitely antigen specific and highly sensitive. Staining of T cell clones shows no cross-reactions so far (for a review, Refs 11 and 25). Currently standard method for the analysis of antigen-specific T cells is limiting dilution analysis (LDA). The numbers of precursors detected by LDA are often 50-500 times lower than those detected by the other methods. The reason might be that LDA analysis depends on cell proliferation. 26 Peptide/MHC-I tetramers were intensively used for the staining of virus-specific T cells. Study with tetrameric complexes of HLA-A2/HIV gag or pol showed that 2% of CD8 + T cells were antigen specific. 7 For persistent HIV infection, the range is commonly 0.1-2% of CD8 + T cells. In persistent simian immunodeficiency virus infection in macaques, Kuroda et al 26 showed that epitope-specific T cells can account for as much as 10% of CD8 + T cells in the blood. Callan et al 27 have shown that between 7 and 44% of blood CD8 + T cells are EBV-specific in acute infection and the total number of CD8 + T cells is greatly increased, almost entirely by antigen-specific cells. MHC-II based tetramers were also prepared and widely used for the staining of CD4 + T cells. 19, 28 Recently some groups have reported the usage of tetramer for the staining of tumor-specific T cells in human melanoma patients. Our recent investigation has employed H-2K b /peptide tetramer for the analysis of tumor-specific CTL in tumor-bearing mice after immunotherapy with IL-18 gene-modified dendritic cell vaccine and the results demonstrated that tumor-specific CTL could be induced significantly in a CD4
+ T cell-dependent manner after immunization and immunotherapy. 29 In the present study, we prepared B16 specific H-2K b / TRP2 180-188 tetramer and it was used to stain tumor-specific CD8 + T cells after combined IL-18 and CD suicide gene therapy, and the results showed that the CD8 + tetramer + T cells was about 3-5% of the CD8 + T cells. The CTL cytotoxicity was efficiently induced in mice after combined therapy with AdIL18/AdCD/5FC, suggesting efficient induction of tumor-specific CD8 + T cells after combined gene therapy with AdCD/5FC and AdIL18. The results obtained from tetramer staining and CTL cytotoxicity assay correlated significantly, indicating that MHC-I/peptide tetramer could be used efficiently for the direct analysis of tumor-specific CTL.
Recent studies have documented that CD4 + T cells played central roles in the antitumor immune response. 30, 31 First, helper T cells play critical roles in the initiation, induction and amplification of antitumor immunity, especially CTL activity. 32, 33 Second, Th1 type cytokine IL-2, IFN␥ and Th2 cytokine IL-4, IL-5 are potent stimulators for NK cells, macrophages, eosinophils etc, which are very important effector cells for the eradication of tumor cells in vivo. IL-18 can increase NK activity both in vivo and in vitro. 34, 35 Augmented CTL activity and type 1 cytokine production from NK cells and T cells was also reported by IL-18 administration. 16, 17 NK cell activity and Th1 cell response was significantly impaired in IL-18 −/− mice. 36 IL-18 was also reported to enhance Fas ligandmediated cytotoxicity of murine T helper 1 cells. 37 We hypothesized that Th1 type cytokine IL-18 might enhance the induction of antitumor immunity of suicide gene therapy. In the present investigation, we have illustrated that IL-18 gene transfer could activate cytotoxicity of NK and macrophages. NK and macrophages are potent tumor-killer cells in tumor-bearing host after activation by cytokines such as IL-2 and INF-␥. Therefore, we speculated that IL-18 gene transfer could efficiently enhance the induction of tumor-specific CTL and nonspecific antitumor immunity in the tumor bearing-host, thus augmenting the antitumor efficacy of suicide gene therapy.
To conclude, a combination of CD suicide gene and IL-18 gene therapy elicited more potent antitumor effects in the pre-established B16 melanoma. Efficient induction of antitumor immunity of the tumor-bearing mice was speculated to be a key element in the improved antitumor efficacy of the combined CD and IL-18 gene therapy.
Materials and methods

Animals and cell lines
Male or female wild-type C57BL/6 (H-2 b ) mice, 6-8 weeks of age, provided by joint venture SIPPR-BK Experimental Animal Co, Shanghai, China, were housed in specific pathogen-free state for all experiments. The C57BL/6-derived B16 melanoma cells, NK sensitive YAC-1 cells and 293, a continuous cell line derived from human embryonic kidney, L1210 murine leukemia cells, were maintained in RPMI-1640 medium supplemented with penicillin 100 U/ml, streptomycin 100 g/ml, 2-mercaptoethanol 50 mm and 10% fetal calf serum (FCS). FCS was provided by Shanghai Institute of Biological Products, Shanghai, China, and all culture media were purchased from Gibco-BRL, Grand Island, NY, USA.
Preparation of tetramers
The DNA coding for a specific biotinylation site with 13 amino acids 7, 38 was fused to the COOH terminus of the non-transmembrane regain (residue 1-280) of H-2K b heavy chain with the upstream primer 5′ CTA GCT AGC GGC CCA CAC TCG CTG AGG 3′ and downstream primer 5′ CGC GGA TCC TTA ACG ATG ATT CCA CAC CAT TTT CTG TGC ATC CAG AAT ATG ATG CAG GGA TCC AGT GGA TGG AGG AGG CTC 3′. H-2K b expression plasmid pLKb1.1, a kind gift from Dr MJ Shields, NCI, NIH, was subjected as template to 35 cycles of 94°C for 1 min, 56°C for 1 min, 72°C for 1 min, and a final 15 min at 72°C using PCR beads (Amersham-Pharmacia, Piscataway, NJ, USA). The amplified PCR product was cut with NheI/BamHI restriction enzymes (New England Biolabs, Beverly, MA, USA), gel-purified and ligated into pET21d vector (Novagen, Madison, WI, USA) digested with NheI/BamHI. The fusion protein-expressing plasmid and pET 3a harboring human ␤ 2 -microglobulin (provided by Dr MJ Shields, NCI, NIH) were transfected into E. coli BL21 (DE3) as an expression host. The purified complexes were biotinylated for 2 h at 25°C in the presence of biotin in 10 mm Tris-HCl, pH 7.5, containing BirA enzyme 1 m, NaCl at 150 mm, adenosine triphosphate at 5 mm, MgCl 2 at 5 mm (Avidity, Boulder, CO, USA). The biotinylated complexes were further purified by gel filtration and the H-2K b tetramer was prepared by mixing H-2K b and PE-conjugated streptavidin (Biosource International, Camarillo, CA, USA) at a molar ration of 4:1. The tetramer was then stored at 4°C in PBS (pH 7.4) at a concentration of 1 mg/ml in cocktail containing 0.1 sodium azide, 1 g/ml pepstatin, 1 g/ml leupeptin and 1 g/ml aprotinin. 40 Recombinant adenovirus preparation Replication-defective recombinant adenovirus AdlacZ encoding ␤-galactosidase and AdCD encoding E. coli CD were kindly provided by Dr Hamada (Department of Molecular Biotherapy Research, Cancer Institute, Tokyo, Japan). AdIL18 encoding murine IL-18 were constructed from human adenovirus serotype 5 using homologous recombination. The expression of these genes was driven by CAG promoter. 41 These adenoviruses were propagated in 293 cells and the titers of the adenovirus were determined with a standard plaque forming unit (p.f.u.) assay.
Combined suicide gene and IL-18 gene therapy For combined suicide gene and IL18 gene therapy, B16 melanoma cells were taken from continuous culture and resuspended in PBS for inoculation into mice. Wild-type C57BL/6 mice were inoculated s.c. with 5 × 10 4 B16 cells to prepare an in vivo tumor model. Three days after tumor inoculation, the tumor-bearing mice were divided into five groups with 20 mice in each group and the mice in each groups were injected intratumorally with any of Gene Therapy the following preparations: PBS, AdlacZ, AdCD, AdIL18, AdCD plus AdIL18. Injections of the viruses of 10 9 in 0.1 ml PBS was performed 3 days after the inoculation of tumor cells and a booster of the same injections was given after 7 days. Twenty-four hours after the first injection of adenoviruses, 5FC (Sigma Chemical, St Louis, MO, USA) 300 mg/kg was injected i.p. into AdlacZ-, AdCD-, or AdCD/AdIL18-treated mice, and 5FC administration was performed for 10 consecutive days. The tumor-bearing mice were killed 3 days after the last injection of 5FC and the tumors were weighed. Three months after tumor inoculation, the tumor-bearing mice were rechallenged with 2 × 10 4 B16 cells and tumor-free mice were monitored 3 months later.
In vivo depletion of specific cell subsets Monoclonal antibodies (McAbs) used to deplete cell subsets were prepared from the hybridomas GK1.5 (anti-CD4, ATCC TIB207), 2.43 (anti-CD8, ATCC TIB210), or PK136 (anti-NK1.1, ATCC HB-191) (ATCC, Manassas, VA, USA). Ascites containing 0.1 mg of McAb in 0.1 ml PBS were injected i.p. into each mice 4 and 1 days before tumor inoculation, and another three injections of McAbs were performed 2, 5 and 8 days after tumor inoculation. 42 Flow cytometry analysis of splenocytes and peripheral blood cells revealed that more than 98% of the targeted cells were depleted.
Staining of tumor-specific CD8
+ T cells by tetramer For antigen-specific CD8 + T cell analysis, non-adherent lymphocytes were incubated with H-2K b /TRP2 tetramers for 3 h at 4°C. In the last 30 min of the incubation period, the FITC-conjugated anti-CD8a McAb (Biosource International) was added for further incubation. Cells were analyzed on a Becton Dickinson FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Data acquisition and analysis were performed using CellQuest software.
Cytotoxic assay of CTL and NK cells Splenic lymphocytes were isolated from dead mice 17 days after tumor inoculation. The erythrocytes were depleted with 0.83% ammonium chloride and macrophages were removed by adherence of splenocytes on plastic plates for 2 h. The non-adherent lymphocytes were used as NK effector cells. The lymphocytes were cocultured with inactivated B16 cells (5000 rad) for 7 days in the presence of recombinant human IL-2 20 U/ml, and then collected as CTL effector cells. The NK activity and CTL activity were determined by a standard 4-h c.p.m.) × 100. 43 The CTL showed no cytotoxicity against syngeneic EL4 cells (data not shown).
Macrophage cytotoxicity
The splenocytes were cultured in RPMI-1640 medium for 2 h and the adherent cells were collected as macrophages. For macrophage cytotoxicity assay, the adherent macrophages were incubated with L1210 cells at an effector:target ratio of 10:1 or 20:1 in a total volume of 0.1 ml medium per well in 96-well U-bottomed plate. After 20 h of co-incubation at 37°C, 5% CO 2 and 95% relative humidity, 10 l MTT was added to L1210 cells transferred from macrophage-L1210 cultures. The L1210 cells were then incubated for 4 h in the presence of MTT followed by addition of 0.1 ml of 10% SDS in 0. 01 N HCl. The formazan crystals were dissolved in 10% SDS and the absorbance was read at 540 nm on a Biorad (Hercules, CA, USA) model 2550 microplate reader. The percentage of cytotoxicity was calculated relative to the calibration standard L1210 as follows: percentage of cytotoxicity = 1 − A L1210 remained /A L1210 standard . 5 Cytokine release assay The non-adherent splenocytes at a concentration of 2 × 10 6 cells/ml were stimulated with irradiated B16 melanoma cells (5000 rad). Supernatants were harvested after 24 h for IL-2 assay and 48 h for IFN␥ assay. The cytokines were assayed using ELISA according to the manufacturer's instructions (Endogen, Woburn, MA, USA).
Statistics
Statistical analysis was performed using the Student's t test. A P Ͻ 0.05 was considered to be statistically significant. All experiments were run in triplicate and the results are means ± s.d. of triplicate determinations or representative data of three independent experiments.
